RxDoctor Payments DataLook up a doctor →

Chukwuma Onyewu, MD

Interventional Pain Medicine · Lanham, MDNPI 1578573457

Payments from drug & device makers

$7,817in general payments, 2019–2025

Across 391 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Medtronic$1K
  • AbbVie$800
  • Collegium Pharmaceutical, Inc.$789
  • Abbott$537
  • Boston Scientific$362
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,72699%
  • Education$911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,817 in reported general payments places this provider in the 65th percentile of 56 interventional pain medicine providers in Maryland.

See all interventional pain medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$173,110
Medicare patients
375
Services billed
2,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide47$130,013
BelbucaBuprenorphine Hcl61$48,963
Xtampza ErOxycodone Myristate85$43,008
OxycontinOxycodone Hcl66$24,828
NucyntaTapentadol Hcl13$23,544
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen607$17,394
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl59$17,220
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$14,780
ZtlidoLidocaine29$14,165
Lidocaine134$13,532
Oxycodone Hcl764$13,281
MovantikNaloxegol Oxalate33$12,984
LinzessLinaclotide23$12,102
Diclofenac Sodium239$11,310
Naloxone Hcl132$7,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,335$130,01347 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$789$115,515159 claims
Orexo US, Inc.Zubsolv$221$14,78012 claims
Scilex Pharmaceuticals Inc.Ztlido$339$14,16529 claims
Redhill Biopharma Inc.Movantik$74$12,98433 claims
AbbVieLinzess$800$12,10223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 56 interventional pain medicine providers in Maryland.

Other interventional pain medicine in Lanham

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →